Clinical Trial
Lumbrokinase for Long COVID, Post-treatment Lyme disease, and ME/CFS
The purpose of this study is to test if the dietary supplement, lumbrokinase, may have an effect on the overall symptom burden of several chronic illnesses: Long COVID, Post-Treatment Lyme Disease Syndrome, or Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Is this a virtual opportunity?
No, this is not a virtual opportunity.
What are the location requirements?
You must be located in the USA.
Will there be in-person visits? If so, how many?
Yes, there will be 4 in-person visits.
Where is the study located?
5 East 98th Street, New York, New York, USA.
What is the length of participation?
The length of participation is 12 weeks.
What health qualifications are there to participate?
Long COVID (required proof of COVID infection which caused Long COVID)
Post-Treatment Lyme Disease Syndrome (required proof of Lyme)
ME/CFS (pre-2020 or not related to COVID)
What kinds of tasks are associated with participation?
There will be blood draws, and EndoPat test, surveys, and physical assessments.